

---

**The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable *in vitro* activity against chronic lymphocytic leukemia B cells with CD20 antibodies**

---

*Josée Golay, Greta Ubiali and Martino Introna*

*Center of Cellular Therapy "G. Lanzani, USC Hematology, and Fondazione per la Ricerca Ospedale Maggiore, ASST Papa Giovanni XXIII, Bergamo, Italy*

*Correspondence: [jgolay@asst-pg23.it](mailto:jgolay@asst-pg23.it)  
doi:10.3324/haematol.2017.169334*

## Supplementary Tables

Supplementary Table 1. Characteristics of CLL patients whose samples were used in apoptosis experiments

Patient n°	Gender/age	Years from diagnosis	Binet stage	N° of previous treatment	Years from last treatment	WBC / $\mu$ l	%CD19
1	F/59	6	B	1	2	153.1	97
2	M/63	2	B	0	NA	41.8	86
3	F/50	16	A	2	10	38.5	71
4	M/82	2	B	0	NA	51.0	75

NA: Not applicable

Supplementary Table 2. Characteristics of the CLL patients whose samples were used for cytokine measurements

Patient n°	Gender/age	Years from diagnosis	Binet stage	N° of previous treatment	Years from last treatment	WBC (x1000/ $\mu$ l)	%CD19
5	F/69	1	A	0	NA	32.1	89
6	M/76	6	A	0	NA	103.3	82
7	M/70	2	B	0	NA	53.8	70
8	F/76	4	A	0	NA	66.3	91
9	M/76	9	C	0	NA	55.0	89
10	M/70	11	A	1	10	11.4	53

NA: Not applicable